Search - tctmd.com

Displaying 81 - 100 of 102

Sort: Relevancy | Date

News Daily News

SCAAR: Stent Thrombosis Risk After Primary PCI No Higher With Bivalirudin Than Other Antithrombotics

Todd Neale

February 19, 2015

News Daily News

SCAAR: El Riesgo de Trombosis del Stent Post-PCI Primaria No es Mayor con Bivalirudina que con Otros Antitrombóticos

Todd Neale

February 19, 2015

Presentation TCT 2014

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Presenter: John M. Lasala, Stuart J. Pocock, Deepak L. Bhatt

September 16, 2014

Presentation TCT 2014

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Presenter: Deepak Bhatt

September 16, 2014

Presentation TCT 2014

Definitely To Prevent Stent Thrombosis and MI!

Presenter: Gregg W. Stone

September 15, 2014

Presentation TCT 2014

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Presenter: Nick Curzen

September 15, 2014

Presentation TCT 2014

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux

September 15, 2014

Presentation TCT 2014

Cangrelor II: New Data from the FDA Advisory Board Panel

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Robert A. Harrington

September 15, 2014

Presentation TCT 2014

Cangrelor I: Data Essentials from the Champion Trials

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Deepak L. Bhatt

September 15, 2014

Presentation

Incidence and Impact of Stent Thrombosis after PCI: Comparison of Cangrelor and Clopidogrel

Presenter: Philippe Généreux

April 02, 2014

News Conference News ACC 2014

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

April 02, 2014

Presentation ACC 2014

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

Presenter: Philippe Généreux

March 30, 2014

News Daily News

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

Yael L. Maxwell

February 13, 2014

News Daily News

FDA Panel Rejects Cangrelor for Both PCI, Bridging Indications

Yael L. Maxwell

February 13, 2014

News Conference News ACC 2013

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Yael L. Maxwell

March 09, 2013

News Daily News

Prasugrel, Ticagrelor Show Delayed Action in STEMI Patients

L.A. McKeown

December 05, 2012

News Daily News

Prasugrel y Ticagrelor Retrasan la Acción Antiplaquetaria en Pacientes Víctimas de un STEMI

L.A. McKeown

December 05, 2012

Presentation

Menores Episodios Isquémicos Inmediatos con el Cangrelor en las PCI: Análisis Conjunto de los Ensayos Champion usando la Definición Universal de IM

Presenter: Harvey D. White

March 16, 2012

Presentation

Puenteando la Terapia Antiplaquetaria con Cangrelor en Pacientes que se someten a Cirugía Cardíaca

Presenter: Dominick J. Angiolillo

January 16, 2012

Presentation

Bridging Antiplatelet Therapy with Cangrelor in Patients Undergoing Cardiac Surgery

Presenter: Dominick J. Angiolillo

January 16, 2012

Advertisement

SCAAR: Stent Thrombosis Risk After Primary PCI No Higher With Bivalirudin Than Other Antithrombotics

SCAAR: El Riesgo de Trombosis del Stent Post-PCI Primaria No es Mayor con Bivalirudina que con Otros Antitrombóticos

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Definitely To Prevent Stent Thrombosis and MI!

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Cangrelor II: New Data from the FDA Advisory Board Panel

Cangrelor I: Data Essentials from the Champion Trials

Incidence and Impact of Stent Thrombosis after PCI: Comparison of Cangrelor and Clopidogrel

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

FDA Panel Rejects Cangrelor for Both PCI, Bridging Indications

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Prasugrel, Ticagrelor Show Delayed Action in STEMI Patients

Prasugrel y Ticagrelor Retrasan la Acción Antiplaquetaria en Pacientes Víctimas de un STEMI

Menores Episodios Isquémicos Inmediatos con el Cangrelor en las PCI: Análisis Conjunto de los Ensayos Champion usando la Definición Universal de IM

Puenteando la Terapia Antiplaquetaria con Cangrelor en Pacientes que se someten a Cirugía Cardíaca

Bridging Antiplatelet Therapy with Cangrelor in Patients Undergoing Cardiac Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content